Patient ALMA_6_BM (39–60 years, male; coverage 20.86x), presenting with relapsed AML (5% blasts), was classified as AML with mutated NPM1, despite genomic analysis revealing only benign NPM1 variants with the presence of KMT2A-KNL1 fusion. This evidence concerns the gene KMT2A and acute myeloid leukemia.